Vaginal cancer natural history: Difference between revisions

Jump to navigation Jump to search
Line 19: Line 19:


===Surgery related===
===Surgery related===
** Infection
* Infection
** [[VTE]]
* [[VTE]]
** [[Haemorrhage]]
* [[Haemorrhage]]
**[[Vesicovaginal fistula]]
*[[Vesicovaginal fistula]]
**Bladder dysfunction
*Bladder dysfunction
**[[Fever]]
*[[Fever]]
**lymphocyst formation
*lymphocyst formation
**Short Vagina
*Short Vagina


===Radiotherapy related===
===Radiotherapy related===

Revision as of 11:51, 23 January 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Syed Musadiq Ali M.B.B.S.[2]

Vaginal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Vaginal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Staging

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Vaginal cancer natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Vaginal cancer natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Vaginal cancer natural history

CDC on Vaginal cancer natural history

Vaginal cancer natural history in the news

Blogs on Vaginal cancer natural history

Directions to Hospitals Treating Vaginal cancer

Risk calculators and risk factors for Vaginal cancer natural history

Overview

Depending on the extent of the tumor at the time of diagnosis, the prognosis of vaginal cancer may vary. However, the prognosis is generally regarded as good.The 5-year survival rate can also depend on the type of vaginal cancer. For squamous cell carcinoma of the vagina, the 5-year survival rate is 54%. For adenocarcinoma of the vagina, the rate is about 60%. Symptoms are related to local extension of disease, urinary symptoms (eg, frequency, dysuria, hematuria), or gastrointestinal complaints (eg, tenesmus, constipation, melena)

Natural History

  • Vaginal bleeding is the most common clinical presentation of vaginal cancer. Many women are asymptomatic.
  • Vaginal bleeding associated with vaginal cancer is typically postcoital or postmenopausal.
  • A watery, blood-tinged, or malodorous vaginal discharge may also be present[1].
  • A vaginal mass may also be noted by the patient.
  • Symptoms are related to local extension of disease, urinary symptoms (eg, frequency, dysuria, hematuria), or gastrointestinal complaints (eg, tenesmus, constipation, melena)[2].
  • Pelvic pain from extension of disease beyond the vagina is present in 5 percent of patients.
  • 20 percent of women are asymptomatic at time of diagnosis [17-19].
  • These vaginal cancers may be detected as a result of cytologic screening for cervical cancer or may be an incidental finding of a vaginal mass on pelvic examination.

Complications

Surgery related

Radiotherapy related

  • Vaginal dryness[3]
  • Vaginal stenosis
  • Radiation cystitis
  • Radiation proctitis
  • Loss of ovarian function

Prognosis

  • Data from a United States National Cancer Database showed an increased risk of mortality in women with vaginal cancer with stage II or greater disease and/or tumor size >4 cm (five-year survival 65 versus 84 percent in tumors ≤4 cm)[4].
  • Mortality was 51 percent higher in women with melanoma compared with squamous vaginal cancer.
  • Patient prognosis depends primarily on the stage of disease, but survival is reduced among those who are older than 60 years, are symptomatic at the time of diagnosis.
  • In addition, the length of vaginal wall involvement has been found to be associated with survival and stage of disease in vaginal Squamous cell cancer(SCC) patients.
  • Non–DES-associated adenocarcinomas generally have a worse prognosis than Squamous cell cancer(SCC) tumors, but DES-associated clear cell tumors have a relatively good prognosis[5].

References

  1. Choo YC, Anderson DG (August 1982). "Neoplasms of the vagina following cervical carcinoma". Gynecol. Oncol. 14 (1): 125–32. PMID 7095583.
  2. Herbst AL, Ulfelder H, Poskanzer DC (April 1971). "Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women". N. Engl. J. Med. 284 (15): 878–81. doi:10.1056/NEJM197104222841604. PMID 5549830.
  3. Nori D, Hilaris BS, Stanimir G, Lewis JL (October 1983). "Radiation therapy of primary vaginal carcinoma". Int. J. Radiat. Oncol. Biol. Phys. 9 (10): 1471–5. PMID 6629889.
  4. Beller U, Sideri M, Maisonneuve P, Benedet JL, Heintz AP, Ngan HY, Pecorelli S, Odicino F, Creasman WT (2001). "Carcinoma of the vagina". J Epidemiol Biostat. 6 (1): 141–52. PMID 11385773.
  5. Hellman K, Lundell M, Silfverswärd C, Nilsson B, Hellström AC, Frankendal B (2006). "Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina". Int. J. Gynecol. Cancer. 16 (3): 1201–11. doi:10.1111/j.1525-1438.2006.00520.x. PMID 16803507.